Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms HELP
Based on 30,427 articles published since 2009
|||| 45 

These are the 30427 published articles about Pancreatic Neoplasms that originated from Worldwide during 2009-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
476 Editorial Operative blood loss and survival in pancreatic cancer. 2011

Donahue, Timothy R / Reber, Howard A. · ·Pancreas · Pubmed #21160368.

ABSTRACT: -- No abstract --

477 Editorial Borderline resectable pancreatic cancer: what have we learned and where do we go from here? 2011

Katz, Matthew H G / Pisters, Peter W T / Lee, Jeffrey E / Fleming, Jason B. · ·Ann Surg Oncol · Pubmed #21136179.

ABSTRACT: -- No abstract --

478 Editorial The conundrum of pancreatic cysts: are we finally moving the (EUS) needle? 2011

Park, Walter G / Pasricha, Pankaj J. · ·Gastroenterology · Pubmed #21110970.

ABSTRACT: -- No abstract --

479 Editorial Standardizing pancreas research. 2011

Makary, Martin A. · ·Ann Surg Oncol · Pubmed #21104329.

ABSTRACT: -- No abstract --

480 Editorial [Pancreatic resection on carcinoma--importance of staging of the disease]. 2010

Ryska, M. · ·Rozhl Chir · Pubmed #21404510.

ABSTRACT: -- No abstract --

481 Editorial [Standardization in pathologic diagnosis of gastrointestinal and pancreatic neuroendocrine tumors]. 2010

Zheng, Jie. · ·Zhonghua Bing Li Xue Za Zhi · Pubmed #21215092.

ABSTRACT: -- No abstract --

482 Editorial Editorial: Neurolysis for pancreatic cancer pain: same song, different verse? 2010

Virtue, Mark A / Levy, Michael J. · ·Am J Gastroenterol · Pubmed #21131929.

ABSTRACT: Since Kappis first performed percutaneous neurolysis in 1914, investigators have employed innumerable technical variations in an effort to enhance the efficacy. Similar efforts have been underway by endosonographers since Wiersema performed the first endoscopic ultrasound (EUS)-guided celiac plexus neurolysis in 1996. Although such efforts are important, the availability of multiple procedural options is indicative of the controversy and lack of meaningful progress. If one particular method was clearly superior, the other techniques would have become obsolete. Sakamoto et al. present a new method of EUS-guided neurolysis in an attempt to improve the outcomes. Although their data are promising, we eagerly await rigorously designed studies that may validate their findings.

483 Editorial Pancreatic cancer: a neglected killer? 2010

Lancet Oncology, ?. · ·Lancet Oncol · Pubmed #21126681.

ABSTRACT: -- No abstract --

484 Editorial Preface: Gastroenteropancreatic system and its tumors: Part 1. 2010

Vinik, Aaron I. ·EVMS Strelitz Diabetes Research Center, Eastern Virginia Medical School, 855 West Brambleton Avenue, Norfolk, VA 23510-1001, USA. vinikai@evms.edu ·Endocrinol Metab Clin North Am · Pubmed #21095538.

ABSTRACT: -- No abstract --

485 Editorial Foreword: Gastroenteropancreatic system and its tumors: Part 1. 2010

LeRoith, Derek. ·Division of Endocrinology, Metabolism, and Bone Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA. derek.leroith@mssm.edu ·Endocrinol Metab Clin North Am · Pubmed #21095537.

ABSTRACT: -- No abstract --

486 Editorial Molecular and clinical markers of pancreas cancer. 2010

Buxbaum, James L / Eloubeidi, Mohamad A. · ·JOP · Pubmed #21068484.

ABSTRACT: Pancreas cancer has the worst prognosis of any solid tumor but is potentially treatable if it is diagnosed at an early stage. Thus there is critical interest in delineating clinical and molecular markers of incipient disease. The currently available biomarker, CA 19-9, has an inadequate sensitivity and specificity to achieve this objective. Diabetes mellitus, tobacco use, and chronic pancreatitis are associated with pancreas cancer. However, screening is currently only recommended in those with hereditary pancreatitis and genetic syndromes which predispose to cancer. Ongoing work to identify early markers of pancreas cancer consists of high throughput discovery methods including gene arrays and proteomics as well as hypothesis driven methods. While several promising candidates have been identified none has yet been convincingly proven to be better than CA 19-9. New methods including endoscopic ultrasound are improving detection of pancreas cancer and are being used to acquire tissue for biomarker discovery.

487 Editorial Treatment effect or secret nature: long-term remissions in metastatic pancreatic cancer. 2010

Horneber, Markus. · ·Onkologie · Pubmed #20975303.

ABSTRACT: -- No abstract --

488 Editorial Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? 2010

Reni, Michele. · ·World J Gastroenterol · Pubmed #20954273.

ABSTRACT: This paper discusses the rationale for phase III testing of neoadjuvant therapy in patients affected by resectable pancreatic adenocarcinoma. The therapeutic management of patients affected by resectable pancreatic cancer is particularly troublesome due to the aggressiveness of the disease and to the limited efficacy and sometimes unfavourable risk-benefit ratio of the available therapeutic tools. Conflicting data on the role of adjuvant chemoradiation have been reported, while adjuvant single-agent chemotherapy significantly improved overall survival (OS) when compared to surgery alone. However, the OS figures for adjuvant chemotherapy remain disappointing. In effect, pancreatic cancer exhibits a prominent tendency to recur after a brief median time interval from surgery and extra-pancreatic dissemination represents the predominant pattern of disease failure. Neoadjuvant treatment has a strong rationale in this disease but limited information on the efficacy of this approach is available from single arm trials with low levels of evidence. Thus, in spite of two decades of investigation there is currently no evidence to support the routine use of pre-surgical therapy in clinical practice. To foster knowledge on the optimal management of this disease, and to produce evidence-based treatment guidelines, there is no alternative to well designed randomized trials. Systemic chemotherapy is a candidate for testing because it is supported by a more robust rationale than chemoradiation. Combination chemotherapy regimens with elevated activity in advanced disease warrant investigation. Caution would suggest the running of an exploratory phase II randomized trial before embarking on a large phase III study.

489 Editorial 2010 American Pancreatic Association Presidential address: growth of pancreatology brings challenges and opportunities for the APA. 2010

Chari, Suresh T. · ·Pancreas · Pubmed #20944488.

ABSTRACT: -- No abstract --

490 Editorial Pancreatic cancer: molecular, biochemical, chemopreventive, and therapeutic aspects. 2010

Iovanna, Juan / Neira, José Luis. · ·ScientificWorldJournal · Pubmed #20890586.

ABSTRACT: -- No abstract --

491 Editorial Adjuvant radiation therapy for distal pancreatic cancer: is there a role? 2010

Czito, Brian G / Willett, Christopher G. · ·Ann Surg Oncol · Pubmed #20878486.

ABSTRACT: -- No abstract --

492 Editorial Endoscopic ultrasonography and pancreatic cancer - close companions. 2010

Fockens, P. · ·Neth J Med · Pubmed #20876912.

ABSTRACT: -- No abstract --

493 Editorial Vascular resections in pancreatic cancer. 2010

Hackert, Thilo / Büchler, Markus W. ·Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany. ·Updates Surg · Pubmed #20845005.

ABSTRACT: -- No abstract --

494 Editorial The new concept of therapeutic strategy for neuroendocrine tumors: important information from a case report of gastrinoma. 2010

Igarashi, Hisato / Ito, Tetsuhide / Takayanagi, Ryoichi. · ·Intern Med · Pubmed #20823641.

ABSTRACT: -- No abstract --

495 Editorial Refinement of adjuvant therapy for pancreatic cancer. 2010

O'Reilly, Eileen M. · ·JAMA · Pubmed #20823441.

ABSTRACT: -- No abstract --

496 Editorial Small tumors, intermediate models, big hopes. 2010

Siu, Lillian L. · ·J Clin Oncol · Pubmed #20823413.

ABSTRACT: -- No abstract --

497 Editorial Mass spectrometry based proteomic profiling for pancreatic cancer. 2010

Pawa, Nikhil / Wright, James M / Arulampalam, Tan H A. · ·JOP · Pubmed #20818108.

ABSTRACT: -- No abstract --

498 Editorial Distal pancreatectomy: another indication for prophylactic pancreatic stenting? 2010

Dumonceau, Jean-Marc. · ·Gastrointest Endosc · Pubmed #20801287.

ABSTRACT: -- No abstract --

499 Editorial Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. 2010

Evans, Douglas B / Erickson, Beth A / Ritch, Paul. · ·Ann Surg Oncol · Pubmed #20737218.

ABSTRACT: -- No abstract --

500 Editorial Radiofrequency ablation of locally advanced pancreatic adenocarcinoma: an overview. 2010

D'Onofrio, Mirko / Barbi, Emilio / Girelli, Roberto / Martone, Enrico / Gallotti, Anna / Salvia, Roberto / Martini, Paolo-Tinazzi / Bassi, Claudio / Pederzoli, Paolo / Pozzi Mucelli, Roberto. ·Department of Radiology, University Hospital G.B. Rossi, University of Verona, Piazzale L.A. Scuro 10, Verona 37134, Italy. mirko.donofrio@univr.it ·World J Gastroenterol · Pubmed #20653055.

ABSTRACT: Radiofrequency ablation (RFA) of pancreatic neoplasms is restricted to locally advanced, non-resectable but non-metastatic tumors. RFA of pancreatic tumors is nowadays an ultrasound-guided procedure performed during laparotomy in open surgery. Intraoperative ultrasound covers the mandatory role of staging, evaluation of feasibility, guidance and monitoring of the procedure. Different types of needle can be used. The first aim in the evaluation of RFA as a treatment for locally advanced pancreatic ductal adenocarcinoma, in order of evaluation but not of importance, is to determine the feasibility of the procedure. The second aim is to establish the effect of RFA on tumoral mass in terms of necrosis and cytoreduction. The most important aim, third in order of evaluation, is the potential improvement of quality of life and survival rate. Nowadays, only a few studies assess the feasibility of the procedure. The present paper is an overview of RFA for pancreatic adenocarcinoma.